Nureca Limited has informed the exchange regarding Appointment of Ms. Smita Goyal as Additional Director (Whole-time Director) with effect from June 01, 2026.
NURECA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Nureca Limited reported FY26 revenue of ₹1,472.10 million, up 28% from ₹1,146.40 million in FY25, with net profit of ₹2.97 million versus a loss of ₹6.68 million the prior year. However, Q4 FY26 showed a net loss of ₹66.25 million, heavily impacted by ₹83.37 million in fair value losses on investments classified as FVTPL. The Board approved appointment of Ms. Smita Goyal as Additional Director (Whole-time Director) effective June 1, 2026, and Mr. Chander Kant as CFO effective June 27, 2026, replacing Mr. Naresh Gupta who resigned June 26 for better career opportunities. Additionally, the Board approved incremental capex of up to ₹100 crore for manufacturing medical devices at the Derabassi facility and purchase of adjoining land for future expansion. The 10th AGM is scheduled for July 28, 2026.
The company returned to annual profitability despite Q4 losses from investment mark-to-market. The family-dominated board continues with Ms. Smita Goyal's appointment (sister-in-law of CEO), while the ₹100 crore capex approval signals growth investment in medical devices and healthcare products.